2023 World Conference on Lung Cancer (Posters)-EP09.02. A Phase II Study on Aggressive Local Consolidative Therapy in Combination With Chemotherapy for Oligometastic NSCLC: TORG1529

EP09.02. A Phase II Study on Aggressive Local Consolidative Therapy in Combination With Chemotherapy for Oligometastic NSCLC: TORG1529 - PDF(Slides)

Back to course

Pdf Summary

A phase II study was conducted to assess the efficacy and safety of chemotherapy combined with local therapy for non-small cell lung cancer (NSCLC) with oligometastases. The study involved 19 patients who met the eligibility criteria, including age greater than 20, performance status of 0-1, pathologically confirmed NSCLC, and a maximum of three metastases in two organs. The primary endpoint of the study was the 2-year survival rate, while secondary endpoints included progression-free survival and overall survival. <br /><br />Patients received chemotherapy with cisplatin and vinorelbine or cisplatin and docetaxel, followed by thoracic radiotherapy. Local consolidative therapy, such as surgery or radiotherapy, was administered within 8 weeks of starting or completing chemotherapy and radiotherapy. <br /><br />The study found that the 2-year survival rate was 68.4% and the median survival time was 42.1 months. The progression-free survival was 8.6 months. Of the 14 patients who experienced disease progression, 10 received local consolidative therapy. The adverse event profile was generally manageable, with no treatment-related deaths reported. One serious adverse event, an incidental eye disorder, was reported.<br /><br />Based on the results, the study concluded that aggressive local consolidative therapy combined with systemic chemotherapy for stage IV NSCLC with oligometastases showed tolerability and possible efficacy. Further research is needed to confirm the findings and establish optimal treatment strategies for this patient population.

Asset Subtitle

Takaaki Tokito

Meta Tag

Speaker Takaaki Tokito

Topic Metastatic NSCLC: Local Therapies - Integration With Systemic Therapies

Keywords

chemotherapy

local therapy

NSCLC

oligometastases

2-year survival rate

progression-free survival

overall survival

local consolidative therapy

median survival time

tolerability